Review



lpa1 antagonist9  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress lpa1 antagonist9
    Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. <t>LPA1,</t> 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.
    Lpa1 Antagonist9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lpa1 antagonist9/product/MedChemExpress
    Average 93 stars, based on 8 article reviews
    lpa1 antagonist9 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model."

    Article Title: A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model.

    Journal: Journal of pharmacological sciences

    doi: 10.1016/j.jphs.2025.03.012

    Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.
    Figure Legend Snippet: Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.

    Techniques Used: Inhibition, Binding Assay, Membrane, Beta-Arrestin Assay



    Similar Products

    lpa1 antagonist9  (MedChemExpress)
    93
    MedChemExpress lpa1 antagonist9
    Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. <t>LPA1,</t> 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.
    Lpa1 Antagonist9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lpa1 antagonist9/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    lpa1 antagonist9 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.

    Journal: Journal of pharmacological sciences

    Article Title: A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model.

    doi: 10.1016/j.jphs.2025.03.012

    Figure Lengend Snippet: Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.

    Article Snippet: BMS-986020, an LPA1 antagonist9 was purchased from MCE (Monmouth Junction, NJ, USA).

    Techniques: Inhibition, Binding Assay, Membrane, Beta-Arrestin Assay